Cann Reaffirms “Hold” Rating for Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “hold” rating reissued by research analysts at Cann in a report released on Tuesday.
The analysts wrote, “While we have not modeled any revenue impact from AG-270 to either Agios or Celgene by 2022, we believe that AG-270 could be an important value driver for Agios and Celgene. AG-270 is a novel compound in the field of synthetic lethality, and has the potential to address large patient populations. We are not making any changes to our outlook at this time, but we continue to watch the timing of the program closely.””
A number of other analysts have also issued reports on the company. Credit Suisse Group set a $95.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 11th. ValuEngine upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. SunTrust Banks reiterated a “buy” rating and issued a $101.00 price target (up from $80.00) on shares of Agios Pharmaceuticals in a research note on Thursday, February 15th. Finally, JPMorgan Chase lifted their price target on Agios Pharmaceuticals from $76.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $87.00.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The business had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. During the same period in the previous year, the firm posted ($1.34) earnings per share. The firm’s revenue was down 56.7% compared to the same quarter last year. research analysts predict that Agios Pharmaceuticals will post -6.25 EPS for the current year.
In related news, insider Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the transaction, the insider now directly owns 2,881 shares in the company, valued at $245,173.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steven L. Hoerter sold 2,050 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, March 22nd. The stock was sold at an average price of $84.65, for a total value of $173,532.50. Following the completion of the transaction, the insider now owns 2,050 shares of the company’s stock, valued at $173,532.50. The disclosure for this sale can be found here. Insiders sold 159,880 shares of company stock valued at $12,661,668 over the last quarter. Insiders own 5.43% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 762 shares during the period. State of Alaska Department of Revenue acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $160,000. Bank of Montreal Can boosted its stake in Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 1,520 shares during the period. Macquarie Group Ltd. acquired a new position in Agios Pharmaceuticals in the third quarter valued at approximately $245,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $259,000. Institutional investors own 82.41% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cann Reaffirms “Hold” Rating for Agios Pharmaceuticals (AGIO)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/04/16/cann-reaffirms-hold-rating-for-agios-pharmaceuticals-agio.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.